SCB 1019
Alternative Names: RSV F antigen vaccine; SCB-1019; SCB-1019TLatest Information Update: 19 Jun 2025
At a glance
- Originator Clover Biopharmaceuticals
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 07 May 2025 Clover Biopharmaceuticals completes a phase I trial in Respiratory syncytial virus infections (In volunteers, In adults, In the elderly) in Australia (Parenteral) (NCT06194318)
- 24 Mar 2025 Clover Biopharmaceuticals completes enrolment of patients in phase I trial in Respiratory syncytial virus infections (In children) in Australia (NCT06666179)
- 23 Mar 2025 US FDA completes IND application for phase I trial in Respiratory syncytial virus infections